Nuvation Bio Inc.
IBTROZI
advanced ROS1+ NSCLC
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for IBTROZI in advanced ROS1+ NSCLC are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In December 2025, the Company announced the publication of positive results from a Phase 2 study of safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas.”